Bivirkninger (dvs. af investigator antaget at være muligvis, sandsynligvis eller definitivt relateret til lægemidlet) blev rapporteret med sammenlignelige frekvenser for Cubicin og komparative regimer.
Adverse reactions (i. e. considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported at similar frequencies for Cubicin and comparator regimens.